Washington, D.C.-based Danaher Corporation (DHR) is a global life sciences and diagnostics company that develops the tools, technologies and services used to advance biomedical research, manufacture medicines and diagnose diseases. The company has a market cap of $135.3 billion and operates through Biotechnology, Life Sciences, and Diagnostics segments.
DHR is expected to release its Q3 2026 earnings on Wednesday, Oct. 21, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.96 on a diluted basis, up 3.7% from $1.89 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.